PG
UTHR icon

PEAK6 Group’s United Therapeutics UTHR Stock Holding History

PEAK6 Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-15,704
Closed -$1.96M – 5080
2017
Q1 		$2.13M Buy
+15,704
New +$2.38M 0.02% 1093
2016
Q1 		– Sell
-4,543
Closed -$575K – 5072
2015
Q4 		$711K Sell
4,543
-45,969
-91% -$6.69M ﹤0.01% 2254
2015
Q3 		$6.63M Buy
50,512
+50,303
+24,068% +$8.07M 0.03% 703
2015
Q2 		$36K Buy
+209
New +$37.6K ﹤0.01% 4678

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

PEAK6 Group's UTHR Position: Q2 2017 in Review

PEAK6 Group sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 15,704 shares — an estimated $1.96M sold.

PEAK6 Group first reported a position in UTHR in Q2 2015 and held it in 4 quarters. The position peaked at $6.63M in Q3 2015. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

  • PEAK6 Group reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
  • PEAK6 Group sold 15,704 United Therapeutics shares in Q2 2017, an estimated $1.96M.
  • PEAK6 Group first reported a position in United Therapeutics in Q2 2015 and held it in 4 quarters.
  • PEAK6 Group's United Therapeutics position peaked at $6.63M in Q3 2015.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on PEAK6 Group's 13F filing for Q2 2017, filed 14 Aug 2017.